{"id":54354,"date":"2023-02-28T23:07:40","date_gmt":"2023-02-28T22:07:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/"},"modified":"2023-02-28T23:07:40","modified_gmt":"2023-02-28T22:07:40","slug":"toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/","title":{"rendered":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers"},"content":{"rendered":"
\n

\nToragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d)<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for the company\u2019s lead product candidate, TGN-S11, for the treatment of HPV-induced cancers.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe acceptance of the TGN-S11 IND is an important milestone for Toragen, as we work toward a treatment for HPV-induced cancers,\u201d said Sandra Coufal, MD, Toragen\u2019s CEO. \u201cWe are now turning our focus to clinical execution with the commencement of our Phase 1 clinical trial and look forward to beginning to dose patients by mid-2023.\u201d\n<\/p>\n

\nThe Phase 1 clinical trial is a dose escalation trial as well as a dose expansion trial in combination with a checkpoint inhibitor for patients with HPV-induced cancers.\n<\/p>\n

\nAbout Toragen<\/b>\n<\/p>\n

\nToragen, Inc. is targeting the root cause of virally induced cancers. https:\/\/toragen.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nToragen, Inc.
\n
Cheryl Collett
\n
CFO
\n
ccollett@toragen.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54354","6":"format-standard","7":"category-industry"},"yoast_head":"\nToragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-28T22:07:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230228006424\/en\/1726269\/21\/Toragen_Wordmark_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers\",\"datePublished\":\"2023-02-28T22:07:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/\"},\"wordCount\":199,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006424\\\/en\\\/1726269\\\/21\\\/Toragen_Wordmark_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/\",\"name\":\"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006424\\\/en\\\/1726269\\\/21\\\/Toragen_Wordmark_Logo.jpg\",\"datePublished\":\"2023-02-28T22:07:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006424\\\/en\\\/1726269\\\/21\\\/Toragen_Wordmark_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006424\\\/en\\\/1726269\\\/21\\\/Toragen_Wordmark_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/","og_locale":"en_US","og_type":"article","og_title":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers - Pharma Trend","og_description":"Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-28T22:07:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230228006424\/en\/1726269\/21\/Toragen_Wordmark_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers","datePublished":"2023-02-28T22:07:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/"},"wordCount":199,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230228006424\/en\/1726269\/21\/Toragen_Wordmark_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/","url":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/","name":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230228006424\/en\/1726269\/21\/Toragen_Wordmark_Logo.jpg","datePublished":"2023-02-28T22:07:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230228006424\/en\/1726269\/21\/Toragen_Wordmark_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230228006424\/en\/1726269\/21\/Toragen_Wordmark_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-fda-acceptance-of-ind-application-for-tgn-s11-for-the-treatment-of-hpv-induced-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54354"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54354\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}